Afatinib is the second-generation EGFR-TKI that has been shown to improve progression free survival (PFS) of EGFR-mutated NSCLC-BM patients with ORR of 70 ~ 75% and PFS of 8.2 months [85]. Here, EGFR is linked to non-small cell lung carcinoma.